Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled Phase III Trial Evaluating the Role of Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) Non-Small Cell Lung Cancer (NSCLC) Patients

NCT00211952 is registered in ClinicalTrials.gov with Medical University of Gdansk as lead sponsor.

NCT NCT00211952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00211952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled Phase III Trial Evaluating the Role of Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) Non-Small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
Medical University of Gdansk
Phase
Phase 3
Overall status
Suspended
Start date
March 31, 2004
Completion date
Not reported
Enrollment
542
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer